Almotriptan. Antimigraine 5-HT(1D/1B) agonist

Drugs of the Future

Volumn 24, Issue 4, 1999, Pages 367-374

  Palacios, J M ^a   Rabasseda, X ^b   Castaner J ^b  

^a Almirall Prodesfarma SA ^*  (Spain)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (3 FLUOROPHENYL)ETHYL] 4 [3 [5 (1,2,4 TRIAZOL 4 YL) 1H INDOL 3 YL]PROPYL]PIPERAZINE; 1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 4 (4 METHYL 3 PYRROLIDINYL) 1H IMIDAZOLE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 6 ACETYL (3 CHLORO 4 FLUOROBENZOYLAMINO) 3,4 DIHYDRO 2,2 DIMETHYL 2H BENZO[B]PYRAN 3 OL; [4 [4 [2 [3 (2 AMINOETHYL) 1H INDOL 5 YLOXY] ACETYL] PIPERAZIN 1 YL] BENZONITRILE; ALMOTRIPTAN; CALCIUM CHANNEL BLOCKING AGENT; DOTARIZINE; ELETRIPTAN; FROVATRIPTAN; GABAERGIC RECEPTOR AFFECTING AGENT; GANAXOLONE; HISTAMINE H3 RECEPTOR AGONIST; IS 159; LANEPITANT; LOMERIZINE; MDL 747216; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; NARATRIPTAN; NEUROKININ 1 RECEPTOR ANTAGONIST; RIZATRIPTAN; SEROTONIN 1 AGONIST; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN 1F RECEPTOR AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MIGRAINE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033061775     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.04.482252     Document Type: Review

References (17)

1. Fernández Forner, M.D., Puig Duran, C., Crespo Crespo, M.I., Moragues Mauri, J. (Laboratories Almirall SA). Process for the preparation of indole derive. ES 2084560.
2. 1B/1D receptor agonists. Res Disclosure 1998, 412: 1088.
3. Pujol Noguera, F., Crespo Crespo, M.I., Puig Durán, C., Fernández Forner, D., Moragues Mauri, J. (Laboratorios Almirall SA). New indole derivs. ES 2056025.
4. Fernandez Forner, D., Puig Duran, C., Prieto Soto, J., Noverola, A., Moragues Mauri, J. (Laboratorios Almirall SA). Indol derivs. for the treatment of migraine. EP 605697, JP 94511261, US 5565447, WO 9402460.
5. Johnson, K.W., Phebus, L.A., Cohen, M.L. Serotonin in migraine: Theories, animal models and emerging therapies. Prog Drug Res 1998, 51: 219-244.
6. Bou, J., Doménech, T., Gras, J., Beleta, J., Llenas, J., Fernández, A.G., Palacios, J.M. Pharmacological profile of almotriptan, a novel antimigraine agent. Cephalalgia 1997, 17: 421-422.
7. Bou, J., Cardelus, I., Llenas, J., Fernandez, A.G., Palacios, J.M. Antimigraine potential of almotriptan in animal models. Methods Find Exp Clin Pharmacol 1997; 19 (Suppl. A): Abst PA-21.
8. Garcia, E. et al. A clinical trial to determine the lack of food interaction on the bioavailability of almotriptan, a new 5-HT1B/1D agonist, in healthy volunteers. 40th Annu Sci Meet Amer Assoc Study Headache (June 26-28, San Francisco) 1998, Abst 22.
9. Cabarrocas, X., Salva, M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. Cephalalgia 1997, 17: 421.
10. Salva, M., Palacios, J.M., Martinez-Tobed, A. Metabolism of the novel anti-migraine compound almotriptan (LAS 31416) in humans. 6th Eur ISSX Meet (June 30-July 3, Gothenburg) 1997, Abst 174.
11. Robert, M., Cabarrocas, X. et al. Efficacy and tolerability of oral almotriptan in the treatment of migraine. Cephalalgia 1998, 18: A406.
12. 1B/1D agonist. 40th Annu Sci Meet Amer Assoc Study Headache (June 26-28, San Francisco) 1998, Abst 23.
13. 1D agonist. Cephalalgia 1997, 17: 421.
14. 1B/1D agonist, compared with sumatriptan 100 mg. 40th Annu Sci Meet Amer Assoc Study Headache (June 26-28, San Francisco) 1998, 155.
15. 1D agonist. Cephalalgia 1997; 17 (3): 420.
16. Robert, M., Warrington, S. et al. Electrocardiographic effects and pharmacokinetics of oral almotriptan in healthy subjects. Cephalalgia 1998, 18: A406.
17. Robert, M., Warrington, S. et al. Cardiovascular safety of almotriptan in healthy volunteers. 41st Annu Sci Meet Amer Assoc Study Headache (June 11-13, Boston) 1998, Abst.